OCC.AX

Healthcare Biotechnology

Orthocell Limited

A$0.71
-0.01 -1.39% today

Price History

Not enough data

Key Stats

Market Cap
193.40M
Avg Volume
284,228
EPS
-A$0.05
52W High
A$1.59
52W Low
A$0.67
Div. Yield
0.0%

Analyst Ratings

Buy
0
Str Buy
2
Buy
0
Hold
0
Sell
0
Str Sell

Valuation

Forward P/E
-47.33
P/B Ratio
5.63
P/S Ratio
16.95
EV/EBITDA
-8.61
EV/Revenue
13.42

Margins

Gross Margin 58.7%
Operating Margin (159.8%)
Net Margin (122.0%)
EBITDA Margin (155.8%)

Growth & Returns

Revenue Growth (YoY)
42.3%
Return on Equity
(56.8%)
Return on Assets
(25.5%)

Liquidity & Leverage

Current Ratio
5.97
Quick Ratio
5.62
Debt / Equity
0.03
Total Cash
43.95M
Total Debt
970,192

About

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; OrthoATI, for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for bone, nerve, tendon, muscle, or scar tissue, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

orthocell.com